[의학신문·일간보사=이승덕 기자]Among the six drugs for reimbursement re-evaluation, ‘streptokinase/streptodornase’ and ‘adenine hydrochloride’ were eliminated from the re-evaluation of the drug review evaluation.
Eperisone hydrochloride, adenine hydrochloride, and sodium alginate were approved for benefit only for one indication.
At the ‘2022 7th Drug Reimbursement Evaluation Committee’ held by the Health Insurance Review and Assessment Service, △reevaluation of health insurance drug benefit adequacy in 2022 △deliberate on the adequacy of medical care benefit of the drug applied for decision, and disclosed the results.
Looking at the results of the re-evaluation of benefits, the results of reviewing the efficacy and effects of ‘streptokinase/streptodornase’ for acute inflammatory edema exacerbation due to ankle surgery or trauma to the neck and difficulty in biliary excretion accompanying respiratory diseases were evaluated as not suitable for benefits done.
In addition, in the review result of ‘liver disease in which transaminase (SGPT) is elevated’ of ‘adenine hydrochloride and six component combination drugs’, it was evaluated that there was no benefit adequacy, so these two drugs were rejected from the reevaluation.
Only one effect of ‘sodium alginate’ for improving subjective symptoms of reflux esophagitis was recognized, and it was judged not to be appropriate for the other two effects (gastric/duodenal ulcer, erosive gastritis, improvement of subjective symptoms, hemostasis during gastric biopsy bleeding).
Eperisone hydrochloride was also approved for benefit for painful muscle spasms accompanying musculoskeletal disorders, but it was evaluated as not eligible for benefits for spastic paralysis caused by neurological diseases.
In addition, ‘Almagate’ has an antacid action and symptom improvement effect, and ‘Tyropramide hydrochloride’ has acute spasmodic pain (hepatobiliary colic, abdominal colic due to various causes, renal and ureteral colic), abdominal cramps and pain ( Gastrointestinal dyskinesia, cholelithiasis, cholecystitis, and postoperative adhesions) were recognized for benefit suitability, respectively.
Pharmaceutical companies related to the six ingredients can submit an appeal to the Health Insurance Review and Assessment Service within 30 days of notification of the result, and the submitted content will be discussed at the Pharmaceutical Drug Review and finally decided.
On the other hand, for all three drugs that were supposed to be applied for decision application, △Raybow Tablet 50mg, 100mg (Ildong Pharmaceutical) △Epclusa Tablet (Gilliard Science Korea) △Bosed Non-Tablet (Gilliard Science Korea), the appropriateness of reimbursement when accepting less than the assessed amount It was decided that there is
